| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| Other Sizes |
| Targets |
Fmoc-Gly-OH-15N does not have a specific biological target. It is a stable isotope-labeled compound used as a building block in solid-phase peptide synthesis (SPPS). Its primary function is as a reagent for the synthesis of 15N-labeled peptides and proteins. The compound is not intended to interact with biological targets.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
Fmoc-Gly-OH-15N is not evaluated for traditional in vitro biological activity. Its "activity" is as a chemical reagent for solid-phase peptide synthesis. It is used to incorporate 15N-labeled glycine into peptides for structural and functional studies. No pharmacological in vitro activity is associated with this compound. |
| ln Vivo |
No in vivo activity is applicable for Fmoc-Gly-OH-15N, as it is not a therapeutic agent. Its use is confined to the laboratory for peptide synthesis and biochemical research. The compound is not administered to living organisms for any biological effect.
|
| Enzyme Assay |
Fmoc-Gly-OH-15N is used as a building block in solid-phase peptide synthesis (SPPS). Its performance is assessed by its chemical purity and isotopic enrichment. The compound is typically analyzed by HPLC and mass spectrometry. Its purity is a critical parameter for its use in peptide synthesis.
|
| Cell Assay |
Fmoc-Gly-OH-15N is not used in standard cell culture for pharmacological studies. It is a chemical reagent used in peptide synthesis. Its isotopic labeling allows for the incorporation of 15N into peptides for structural studies. The compound itself is not added to cell culture media.
|
| Animal Protocol |
Animal studies are not conducted with Fmoc-Gly-OH-15N as an active compound. It is used as a building block for the synthesis of 15N-labeled peptides that may later be used in research. The compound is never administered to animals for therapeutic or investigative purposes.
|
| ADME/Pharmacokinetics |
Fmoc-Gly-OH-15N has a molecular weight of 298.30 g/mol and a molecular formula of C17H1515NO4. It is a stable isotope-labeled derivative of Fmoc-protected glycine. The compound is typically stored at room temperature. It is soluble in organic solvents. Fmoc-Gly-OH (unlabeled) has a CAS number of 29022-11-5.
|
| Toxicity/Toxicokinetics |
Toxicological data for Fmoc-Gly-OH-15N are not extensively detailed, as it is a research compound. It is not intended for human or veterinary use. Standard laboratory safety precautions, including the use of personal protective equipment (PPE), should be followed when handling the compound.
|
| References | |
| Additional Infomation |
Fmoc-Gly-OH-15N is a stable isotope-labeled derivative of the standard Fmoc-protected glycine building block. It is primarily used as a building block in solid-phase peptide synthesis (SPPS). The Fmoc group protects the amino group of glycine, allowing for selective deprotection and subsequent coupling reactions. It is not approved for therapeutic use.
|
| Molecular Formula |
C17H1515NO4
|
|---|---|
| Molecular Weight |
298.30
|
| Exact Mass |
298.097
|
| CAS # |
125700-33-6
|
| Related CAS # |
Fmoc-Gly-OH;29022-11-5
|
| PubChem CID |
16213300
|
| Appearance |
White to off-white solid powder
|
| Melting Point |
174-175ºC
|
| LogP |
3
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
22
|
| Complexity |
403
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC=C2C(=C1)C(C3=CC=CC=C32)COC(=O)[15NH]CC(=O)O
|
| InChi Key |
NDKDFTQNXLHCGO-CPZJZEHKSA-N
|
| InChi Code |
InChI=1S/C17H15NO4/c19-16(20)9-18-17(21)22-10-15-13-7-3-1-5-11(13)12-6-2-4-8-14(12)15/h1-8,15H,9-10H2,(H,18,21)(H,19,20)/i18+1
|
| Chemical Name |
2-(9H-fluoren-9-ylmethoxycarbonyl(15N)amino)acetic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3523 mL | 16.7616 mL | 33.5233 mL | |
| 5 mM | 0.6705 mL | 3.3523 mL | 6.7047 mL | |
| 10 mM | 0.3352 mL | 1.6762 mL | 3.3523 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
